CPI-100 + capecitabine

CPI-100 + capecitabine is a combination of two drugs intended for cancer treatment. Capecitabine is an orally administered prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body and acts as an antimetabolite chemotherapy agent, disrupting DNA synthesis and inhibiting tumor cell proliferation. CPI-100 is a code name, but no public evidence in the biomedical literature or clinical trial registries links "CPI-100" to a specific drug, mechanism, or company. No structured product, mechanism, or clinical trial information for "CPI-100" as a distinct entity or in combination with capecitabine is available as of 2024. Capecitabine is used in various combinations for the treatment of multiple cancers, including colorectal, breast, and pancreatic cancer, and is well characterized. **Note:** The identity, mechanism, and developer(s) of "CPI-100" cannot be confirmed with current authoritative sources as of 2024.